Mariana Oncology的动态

?? Following on from our poll a couple of weeks ago, we're bringing you a deeper dive into the topic of oncology drugs! ?? Did you know that less than 1% of the oncology drugs in pre-clinical development make it to market? Hence why the work of companies like Onward Therapeutics is so important! Armand de Gramont, co-founder and CSO of Onward Therapeutics, spoke to us for our June newsletter: he described how his company fast-tracks promising cancer treatments to the clinic, with the aim of giving patients more options in the fight against this disease. ?? Check out the full article here: https://lnkd.in/gpdyR4bS

Mainly for biologics, as a complement of their "original" Intra-Veinous (IV) version, Cancer Drug Sub-Cutaneous (SC) version are delivering major benefits to the patients. A Cancer Drug's IV+SC-deliverable unique-formulation, developed as such from the start, has unfortunately never been developed yet but will be incredibly beneficial for all: manufacturers would produce only one product, developers would study 2 routes of administration of the same drug, physicians would have the choice between IV&SC and patients would benefit from the best treatment option, evolving from one route to the other. Any thoughts ? To dive deeper in this subject: Are Subcutaneous Drugs the Key to Cancer Care’s Future? (oncologynewscentral.com)

NEW! Advancing Drug Development in Oncology infographic: Citeline and ICON plc Biotech surveyed over 100 professionals to explore their latest pain points and future directions in cancer treatment: https://ow.ly/58JU50TLSgk. The landscape of oncology drug development has undergone huge advancements over recent years, creating both new opportunities and challenges for biotechs. Interested in what’s driving the future of oncology? View a snapshot of the findings.

Discover what HCPs are saying about the future of #Oncology treatments. Our research highlights six emerging #cancer drugs that #HCPs have shared their opinions about online: - Immunotherapies - Targeted therapies - CAR-T cell therapies - Antibody-drug conjugates - Vaccines for cancer - Radiopharmaceutical therapies Download our whitepaper for in-depth insights into HCP perspectives on the future of Oncology. #ASCO24 https://lnkd.in/et3Fcsmh

Traditional chemotherapy has long been a cornerstone of cancer treatment, but it often comes with significant side effects. Enter Antibody-Drug Conjugates (ADCs), which offer a more targeted approach by harnessing the power of monoclonal antibodies and cytotoxic drugs. Our latest blog discusses the composition, mechanism of action, and bioanalytical strategies essential for developing these promising therapies. Discover how ADCs are setting a new standard in oncology. #CancerTreatment #Oncology #AntibodyDrugConjugates #Pharma #ClinicalBioanalysis #InnovationInHealthcare Read more: https://hubs.li/Q02MCyL00

Traditional chemotherapy has long been a cornerstone of cancer treatment, but it often comes with significant side effects. Enter Antibody-Drug Conjugates (ADCs), which offer a more targeted approach by harnessing the power of monoclonal antibodies and cytotoxic drugs. Our latest blog discusses the composition, mechanism of action, and bioanalytical strategies essential for developing these promising therapies. Discover how ADCs are setting a new standard in oncology. #CancerTreatment #Oncology #AntibodyDrugConjugates #Pharma #ClinicalBioanalysis #InnovationInHealthcare Read more: https://hubs.li/Q02MCwXl0

How will #precisiononcology evolve in the upcoming year? Laksh Aithani, CEO of CHARM Therapeutics, shares his insights on the future of oncology in Scrip Asks' latest feature, "What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances." Laksh predicts significant advancements in precision oncology in 2024, particularly in the development of PRMT5 inhibitors for MTAP-deleted cancers, as well as the introduction of state-of-the-art ROS1 and ALK inhibitors in lung cancer treatments. Discover more about the predictions made by #biopharma leaders regarding the impact of #AI and innovative drug development strategies for 2024:?https://lnkd.in/eNRMWRb8 #drugdevelopment #healthcareinnovation #CHARMTherapeutics

How can we inspire adoption of innovative cancer diagnostics? Communication between industry, pharmaceutical companies, oncologists, and pathologists is key to ensuring rapid tumour diagnosis in breast cancer. And use of MammaTyper? is a way to enable innovation. As Dr Dario DeBiase says, MammaTyper? means you can continue to work well, whilst adding in “another tool to help you provide more reliable results.”? #BreastCancerDiagnosis #CancerInnovation

?? What’s in Your Pipeline? ?? Oncology leads the way in Pharma R&D! Anti-cancer drugs remain a top priority for the world's leading pharma companies, making up 40.1% of drugs in development—a leap from 26.8% in 2010. ?? With a growing focus on oncology, the industry continues to drive innovation and hope for more effective cancer treatments. ???? #oncology #freezedrying #cancertreatments

Delighted to announce the publication of our article 'Prognostic Biomarkers for Triple-Negative Breast Cancer: A Narrative Review' in the International Journal of Pharmaceutical Sciences. This work sheds light on the critical markers that could revolutionize the prognosis and treatment of triple-negative breast cancer. #BreastCancerAwareness #MedicalResearch #InnovationInHealthcare"